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Cell surface receptors are responsible for regulating cellular function on the front line, the
cell membrane. Interestingly, accumulating evidence clearly reveals that the members of
cell surface receptor families have very similar extracellular ligand-binding regions but oppo-
site signaling systems, either inhibitory or stimulatory. These receptors are designated as
paired receptors. Paired receptors often recognize not only physiological ligands but also
non-self ligands, such as viral and bacterial products, to fight infections. In this review,
we introduce several representative examples of paired receptors, focusing on two major
structural superfamilies, the immunoglobulin-like and the C-type lectin-like receptors, and
explain how these receptors distinguish self and non-self ligands to maintain homeostasis
in the immune system. We further discuss the evolutionary aspects of these receptors as
well as the potential drug targets for regulating diseases.
Keywords: paired receptor, immunoglobulin-like receptor, c-type lectin-like receptor, infectious diseases, tumorige-
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PAIRED RECEPTORS
Paired receptors are related membrane proteins that are mainly
expressed on immune cells. They share significantly conserved
amino acid sequences within the extracellular domains, but have
both activating and inhibitory members. The inhibitory recep-
tors possess the immunoreceptor tyrosine-based inhibitory motif
(ITIM) within the cytoplasmic region. In contrast, the activat-
ing receptors have short cytoplasmic regions and a positively
charged residue (Arg or Lys) in the transmembrane domain to
associate with an adaptor protein possessing the immunorecep-
tor tyrosine-based activation motif (ITAM). They are located in
small gene clusters on a chromosome, and are usually expressed
on overlapping immune cells.
Although most of the inhibitory receptors can bind to the
endogenous ligands, it has been somewhat more difficult to iden-
tify the ligands of the activating receptors (Table 1), and their
functions have not been determined. The typical immune cell
receptor-ligand interaction is quite weak (K d in the µM range;
Table 2), with fast association and dissociation. When the activat-
ing and inhibitory receptors specifically recognize the same ligand,
the inhibitory receptors usually have higher affinity (Table 2). This
indicates that the inhibitory receptors function in the maintenance
of immunological tolerance by the recognition of self-ligands, such
as major histocompatibility complex class I molecules [MHCIs,
also referred to as human leukocyte antigen class I molecules
(HLAIs)]. Especially, in natural killer (NK) cells, which lack a gene
arrangement system to recognize foreign antigens, the inhibitory
receptors for MHCIs recognize and eliminate cells that fail to
express MHCIs, due to viral infections or tumor formation. This
hypothetical mechanism is known as the “missing-self hypothesis”
(Ljunggren and Karre, 1990). Based on this hypothesis, Valiante
et al. (1997) suggested a model in which each NK cell expresses
at least one inhibitory receptor for the classical MHCIs, to avoid
killing healthy self-cells. However, a subpopulation of human NK
cells that lack inhibitory receptors for self-MHCIs was identi-
fied (Cooley et al., 2007). Furthermore, there are populations of
“licensed” and “unlicensed” NK cells, which are exposed and not
exposed to self ligands for inhibitory receptors, respectively. Unli-
censed NK cells are basically hyporesponsive, but seem to have
important roles in tumor elimination and viral clearance.
The immune system is considered to be tightly regulated by
the balance between the activating and inhibitory signals through
these paired receptors, and dysregulation of this balance often
causes autoimmunity, allergy, and various infectious diseases.
IMMUNOGLOBULIN-LIKE RECEPTORS
The immunoglobulin (Ig)-like receptors include the killer cell Ig-
like receptors (KIRs), leukocyte Ig-like receptors (LILRs), murine
paired Ig-like receptors (PIRs), Fc receptor, leukocyte-associated
inhibitory receptors (LAIRs), NKp46, and so on. They have sev-
eral conserved extracellular domains possessing a characteristic
Ig-fold, consisting of 70–110 amino acids with a sandwich-like
structure formed by two sheets of antiparallel β strands. A large
number of Ig-like receptor genes are located within the leuko-
cyte receptor complex (LRC) on human chromosome 19 and on
mouse chromosome 7, the syntenic region in the mouse. Here, we
discuss the ligands and the molecular recognition of several Ig-like
receptors.
KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTORS
The KIRs are expressed on NK cells and some subsets of T cells,
and consist of 15 functional inhibitory (KIR2DL and KIR3DL) and
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Table 1 | Paired receptors and their ligands.
Receptor Function Endogenous ligand Non-self ligand
KIR2DL1 Inhibitory HLA-C (group 2)
KIR2DL2 Inhibitory HLA-C (group 1, a subset of group 2), some HLA-B
KIR2DL3 Inhibitory HLA-C (group 1, a subset of group 2), some HLA-B
KIR2DL4 Activating? HLA-G
KIR2DL5 Inhibitory ?
KIR3DL1 Inhibitory HLA-Bw4, a subset of HLA-A
KIR3DL2 Inhibitory HLA-A3, A11 CpG ODN
KIR3DL3 Inhibitory ?
KIR2DS1 Activating HLA-C (group 2)
KIR2DS2 Activating HLA-C (group 1)?
KIR2DS3 Activating HLA-C (group 2)?
KIR2DS4 Activating A subset of HLA-Cw4, A11
KIR2DS5 Activating ?
KIR3DS1 Activating HLA-Bw4, a subset of HLA-A?
LILRB1 Inhibitory HLA-A, B, C, E, F, G CMV UL18
LILRB2 Inhibitory HLA-A, B, C, E, F, G, ANGPTLs (Zheng et al., 2012)
LILRB3-5 Inhibitory ?
LILRA1 Activating HLA-B27, HLA-CfHC
LILRA2, 4–6 Activating ?
LILRA3 Soluble HLA-CfHC, HLA-A, HLA-G
PIR-B Inhibitory MHCI (Nakamura et al., 2004)
Nogo, MAG, OMgp (Atwal et al., 2008)
ANGPTLs (Zheng et al., 2012)
PIR-A Activating MHCI (Nakamura et al., 2004)
PILRα Inhibitory CD99, PANP, NPDC1, COLEC12 HSV-1 gB
PILRβ Activating CD99 HSV-1 gB
SIRPα Inhibitory CD47, SP-A, SP-D
SIRPβ Activating SP-D
SIRPγ No signal CD47
DCIR Inhibitory ?
DCAR Activating ?
NKRP1-A Activating LLT1
NKRP1-D Inhibitory Clrb (Iizuka et al., 2003)
NKRP1-C, F Activating Clrg (Iizuka et al., 2003)
Ly49A, C, I, etc Inhibitory H-2 CMV m157
Ly49D, H, etc Activating CMV m157, others?
CD94/NKG2A Inhibitory HLA-E (Qa-1)
CD94/NKG2C, E Activating HLA-E (Qa-1) Others?
MAIR-I Inhibitory ?
MAIR-II Activating ?
CD200R1 Inhibitory CD200 (Wright et al., 2003)
CD200R3,4 Activating ?
ANGPTLs, angiopoietin-like proteins; fHC, free heavy chain; Nogo, neurite outgrowth inhibitor; MAG, myelin-associated glycoprotein; OMgp, oligodendrocyte myelin
glycoprotein; Clrb, C-type lectin-related molecule b.
activating (KIR2DS and KIR3DS) receptors. The KIRs are divided
into two major haplotypes (haplotype A and haplotype B) and
are encoded together with the LILRs (described later), forming a
gene cluster within the LRC (Figure 1A). The KIR family is highly
polymorphic, with not only nucleotide sequence polymorphisms
but also the presence/absence of each locus. The KIRs basically rec-
ognize the classical MHCIs (HLA-A, -B, or -C) in an allele-specific
fashion. The KIRs are classified into two structural groups, KIR2D
and KIR3D, which have two and three Ig-like domains (D1–D2,
D0–D2, or D0–D1–D2) in the extracellular region, respectively
(Figure 2).
KIR2DL1 specifically binds to HLA–C group 2 molecules
(Asn77 and Lys80), while KIR2DL2/2DL3 bind to HLA–C group
1 molecules (Ser77 and Asn80; Parham, 2005). The ligands of the
KIR2DSs reportedly recognize the same MHCI molecules as those
bound by their related inhibitory KIRs (Parham, 2005). In contrast
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Table 2 | Examples of binding affinities of receptor-ligand interactions.
Receptor Ligand K d (µM) Reference
LILRB1 HLA-G1 2.0 Shiroishi et al. (2003)
LILRB1 HLA-B35 8.8 Shiroishi et al. (2003)
LILRB1 HLA-Cw4 6.5 Shiroishi et al. (2003)
LILRB1 UL18 0.0021 Chapman et al. (1999)
LILRB2 HLA-A11 45 Shiroishi et al. (2003)
LILRB2 HLA-G1 4.8 Shiroishi et al. (2003)
LILRB2 HLA-B35 26 Shiroishi et al. (2003)
LILRB2 HLA-Cw4 14 Shiroishi et al. (2003)
LILRB2 HLA-Cw7 26 Shiroishi et al. (2003)
KIR2DL1 HLA-Cw4 7.2 Stewart et al. (2005)
KIR2DS1 HLA-Cw4 30 Stewart et al. (2005)
KIR2DL3 HLA-Cw7 7.0 Maenaka et al. (1999)
KIR3DS1 HLA-B27 7.0 Li et al. (2010)
PILRα CD99 2.2 Tabata et al. (2008)
PILRβ CD99 85 Tabata et al. (2008)
SIRPα CD47 ∼2.0 Brooke et al. (2004)
SIRPγ CD47 ∼23 Brooke et al. (2004)
NKRP1 LLT1 48 Kamishikiryo et al. (2011)
NKG2A/CD94 HLA-E 0.8–12.4 Kaiser et al. (2008)
NKG2C/CD94 HLA-E 5.2–18.2 Kaiser et al. (2008)
to the T cell receptors (TCRs), which recognize a wide area of the
bound peptide and its surrounding area (α1 and α2 helices) of the
MHCIs (Figure 3A), KIR2Ds bind to the C-terminal site of the
bound peptide (Maenaka et al., 1999; Boyington et al., 2000; Fan
et al., 2001). This peptide-dependent recognition (Figure 3B) is
relatively less specific than that of the TCRs.
KIR3DL1 binds to HLA–B with the Bw4 epitope, determined
by amino acid positions 77–83 (Parham, 2005). KIR3DL2 rec-
ognizes some HLA-A alleles (Parham, 2005). A recent structural
study of the KIR3D-MHCI complex revealed that, while the addi-
tional N-terminal Ig-like domain (D0) bound to the bottom of the
α2 and α3 domains, the C-terminal two Ig-like domains (D1 and
D2) exhibited essentially the same binding mode as the KIR2Ds
(Vivian et al., 2011). This explains the common peptide-dependent
MHCI recognition of the KIR members. On the other hand, the
KIRs have both inhibitory and activating members, and basically
the activating KIRs exhibit much lower or non-detectable affinity
to MHCIs than the inhibitory ones. It is potentially possible that
some peptides can bind more strongly to the activating KIRs than
the inhibitory ones, even though Stewart et al. (2005) demon-
strated that most (or maybe all) peptides did not follow this
characterization. Interestingly, recent reports demonstrated that
the peptide mutations are likely to play a pivotal role in regulating
human immunodeficiency virus (HIV) infection, by mediating
KIR recognition (Thananchai et al., 2009; Alter et al., 2011). This
illustrates some similarity between the KIR and TCR functions,
but in the opposite way (KIR may have a more inhibitory role, but
that of TCR is stimulatory).
Unexpectedly, KIR3DL2 was recently found to bind to the
microbial CpG oligonucleotide (ODN), and the D0 domain is
primarily involved in this recognition. The internalization of the
KIR3DL2-ODN complex causes the activation of NK cells through
toll-like receptor 9 (TLR9) signals (Sivori et al., 2010). As a novel
ligand recognition system, KIR would directly bind to microorgan-
isms and take advantage of non-self ligands in order to regulate
the host immune system.
Recently, KIR2DS2 and KIRDS4 were reported to be up-
regulated after hematopoietic cell transportation, and their up-
regulations were significant in cytomegalovirus viremia (Gallez-
Hawkins et al., 2011). This suggested that the expression levels of
KIRs are also important for controlling NK cell or T cell func-
tion. Furthermore, the KIR expression on cord blood T cells was
induced during a human congenital infection with Trypanosoma
cruzi, possibly by epigenetic mechanisms.
LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTORS
The Leukocyte immunoglobulin-like receptor (LILR; LIR, ILT,
CD85) family was initially identified as the cellular counter struc-
ture to the viral UL18 protein, an MHCI homolog expressed
by human cytomegalovirus (hCMV; Cosman et al., 1997). To
date, 13 LILR family genes, including two pseudogenes (LILRP1
and LILRP2), have been identified. The LILR family members
can be divided into three classes: the inhibitory LILRs (LILRB1,
-B2, -B3, -B4, -B5) with ITIM-like sequences, the activating
LILRs (LILRA1, -A2, -A4, -A5, -A6) with a positively charged
Arg residue in the transmembrane domain pairing with the
FcRγ chain containing an ITAM, and the soluble LILR (LILRA3)
with no transmembrane region. The LILRs have a broad cellu-
lar distribution that includes NK, T, and B lymphocytes, as well
as myelomonocytic cells such as macrophages, mast cells, and
dendritic cells.
The LILR family genes are encoded within the LRC on human
chromosome 19q13 (Figure 1A). In the syntenic region of the
mouse, at the proximal end of chromosome 7, the LILR gene-
orthologous Pir-a and Pir-b are located. There are two clusters of
LILR genes (LILR centromeric and LILR telomeric) that are tran-
scribed in opposite directions (Figure 1A). The similarity of their
amino acid sequences with that encoded by KIR suggests that the
LILRs and KIRs are related by a recent gene duplication event.
LILR genes have been found in a wide variety of species and are
more stable in number, in contrast to the KIR genes. However,
in addition to the deletion of the LILRA3 gene which is absent in
some individuals, recent studies revealed that LILRA3 and LILRA6
show high levels of genetic diversity, with decreased copy num-
bers in Asians (Hirayasu et al., 2008) and increased variability in
Africans (Sudmant et al., 2010).
Although the KIR and LILR protein families are structurally and
functionally comparable, there are some distinguishing character-
istics. LILRB1 and LILRB2 bind to a variety of MHCIs through
two N-terminal extracellular domains (D1 and D2; Borges et al.,
1997; Colonna et al., 1997; Cosman et al., 1997). They recognize
MHCIs on target cells to mediate inhibitory signals, to prevent
the killing of normal cells expressing MHCIs. In other words,
abnormal cells expressing few or no MHCIs can activate the
cellular function of LILRB1/B2-positive leukocytes, due to the
lack of the LILRB1/B2-mediated inhibitory signal. LILRA1 and
LILRA3 also bind to some MHCIs (Allen et al., 2001; Ryu et al.,
2011). Whereas most KIRs recognize discrete polymorphic epi-
topes within the α1 and α2 domains of MHCIs (Figure 3B),
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FIGURE 1 | (A) Schematic representation of the LRC on human
chromosome 19q13.4. A large number of Ig-like receptor genes,
including two clusters of LILR loci and a cluster of KIR loci, are encoded
within the LRC. Arrows indicate the direction of transcription for each
gene.These loci have evolved by multiple duplications, and the two LILR
clusters are likely to have been generated by the inverse duplication of
an ancient one. (B) The hypothesis of paired receptor family evolution. I)
The NK cell possesses at least one inhibitory receptor (cyan), and the
inhibitory signals through it protect the normal self-cells from NK cell
killing. II) In the infected cells, the low level expression of MHCIs
induces the NK killing, in a system called the “missing-self hypothesis.”
III) In order to escape the host NK cytotoxicity, some viruses acquired
the expression of MHCI-like molecules (purple), which bind to the
inhibitory receptors. IV) On the other hand, NK cells express activation
receptors (orange), which evolved from the related inhibitory receptors
to trigger NK cell activation.
FIGURE 2 | Domain configuration of the KIRs. The extracellular Ig-like domain is classified into three types, D0, D1, and D2, dependent on the sequence
homology. KIR2DL4 possesses an ITIM motif, but also associates with the FcRγ chain.
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FIGURE 3 | Comparison of the recognition modes of the MHCI/MHCI
receptors. The complex structures of HLA-A2 and TCR (red; A, PDB ID:2VLR),
HLA-Cw4 and KIR2DL1 (orange; B, PDB ID:1IM9), and HLA-G and LILRB2
(yellow; C, PDB ID: 2DYP). The MHCIs (heavy chain in green, β2m in cyan,
peptide in magenta) are recognized in different manners. (A) TCR binds to the
center of the peptide and the α1–α3 domain of HLA-A2. (B) KIR2DL1 binds to
both the α1 and α2 helices of HLA and the C-terminal end of the peptide. This
binding region contains the 77N/S and 80K/N residues, which determine the
ligand specificity. (C) LILRB2 binds to the α3 domain and β2m, which are
conserved regions among the MHCIs.
a characteristic consistent with their narrow binding specifici-
ties, LILRB1/B2 binding is mediated via a site in the conserved
α3 and β2m domains of the MHCI molecule (Figure 3C; Will-
cox et al., 2003; Shiroishi et al., 2006). Moreover, LILRB1/B2
effectively compete with CD8 for MHCI binding, and modulate
CD8+ T cell activation by blocking CD8 binding as well as by
recruiting inhibitory molecules through their ITIMs (Shiroishi
et al., 2003). This system was also observed in the binding of
the mouse LILRB homolog, PIR-B, to MHCIs (Shiroishi et al.,
2003).
As described above, LILRB1 also binds to the UL18 protein
with much higher affinity than the MHCIs (Cosman et al., 1997),
but LILRB2 and LILRA1 do not (Borges et al., 1997). UL18 is a
highly glycosylated protein (Figure 4A) sharing 25% sequence
identity with MHCIs (Beck and Barrell, 1988). Although the
LILRB1/UL18 complex structure revealed that the binding mode
was conserved with those of the LILRB1/MHCIs (Figures 4A,B),
the residues within the α3 domain differed and created a more
favorable binding region at the interface with LILRB1 (Yang and
Bjorkman, 2008). Moreover, the 13 potential N -glycosylation sites
effectively covered the interaction sites for the potential UL18
binding partners, including the α1–α2 domain binding to KIR
and TCR and the part of α3 domain binding to CD8. On the
other hand, only the binding region of LILIRB1 remains exposed
(Figure 4A). These structural features demonstrated how the viral
protein UL18 can effectively compete with the host ligands for
LILRB1, to regulate the host’s immune response.
PAIRED TYPE 2 IMMUNOGLOBULIN-LIKE RECEPTORS
The Paired type 2 immunoglobulin-like receptors (PILRs) are
expressed mainly on immune cells and have one Ig-like domain
in the extracellular region, with either an ITIM in the intracellu-
lar domain (inhibitory receptor, PILRα) or a positively charged
amino acid in the transmembrane region associated with the
activating subunit, DNAX activating protein of 12 kDa (DAP12;
activating receptor, PILRβ; Fournier et al., 2000). The PILRs rec-
ognize sialylated O-linked sugar-modified mucin and mucin-like
molecules, such as CD99 (Wang et al., 2008), PILR-associating
neural protein (PANP; Kogure et al., 2011), and two newly iden-
tified ligands, neuronal differentiation and proliferation factor-
1 (NPDC1), and collectin-12 (COLEC12; Sun et al., 2012), as
physiological ligands. Notably, the PILR-ligand family is further
expanding, as the report by Sun et al. (2012) described that the
PILRs can also bind to immune cells that do not express any
identified PILR-ligands. As mentioned above, PILRα shows higher
affinity to these ligands than PILRβ, which is typical for paired
receptors in the immune system (Table 2). On the other hand,
recent reports revealed that PILRα is the receptor for herpes
simplex virus 1 (HSV-1), by binding to its glycoprotein B (gB;
Satoh et al., 2008). HSV-1 gB can utilize the inhibitory mem-
ber, PILRα, as an entry receptor, and thus it is probably benefi-
cial for HSV-1 infection. The PILRs recognize physiological and
viral proteins in similar but non-identical manners, and notably
exhibit both sugar- and peptide-dependent binding modes, which
are quite unique for sugar-protein interactions. Even though the
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FIGURE 4 | Structure of UL18/LILRB1 and comparison with the
HLA-A2/LILRB1 complex. (A) The crystal structure of the
UL18/LILRB1 complex (UL18 in green, β2m in cyan, peptide in
magenta, LILRB1 in yellow; PDB ID: 3D2U) with complex carbohydrate
models attached to the 13 potential N -glycosylation sites. The α1–α2
domains recognized by TCR or KIRs are highly glycosylated, and steric
hindrance inhibits effective interactions. Meanwhile, the interface with
LILRB1 still is exposed. (B) The crystal structure of the HLA-A2/LILRB1
complex (HLA-A2 and peptide in purple, β2m in cyan, LILRB1 in yellow;
PDB ID: 1P7Q).
structural information about the PILRs is still lacking, mutage-
nesis studies suggested that the PILR-ligand recognition modes
are somewhat similar to those of the sialic acid-binding Ig-like
lectins (Siglec) family, which can bind to sialic acid (Tabata et al.,
2008; Wang et al., 2008). However, the significant and unusual
characteristic, that the PILRs cannot bind to either sugars or
peptides only, and require both for binding, is largely unknown
and rather unique. Future studies, especially crystallographic and
NMR analyses, will clarify the molecular mechanisms of these
binding systems.
SIGNAL REGULATORY PROTEINS
The Signal regulatory proteins (SIRP) family has three mem-
bers, SIRPα, SIRPβ, and SIRPγ. SIRPα (SHPS-1, BIT, CD172A)
is broadly expressed on myeloid cells, such as neutrophils,
macrophages, and dendritic cells, as well as on neurons (Adams
et al., 1998). SIRPα interacts with CD47, which expresses in hemo-
poietic cells, epithelial cells, and endothelial cells, as well as in
brain and mesenchymal cells, resulting in the transmission of
the inhibitory signal through the SH2-domain-containing pro-
tein tyrosine phosphatases 1 and 2 (SHP1 and 2, respectively), and
finally causes reduced phagocytosis activity in macrophages and
cytokine production in various cells (Barclay and Brown, 2006). In
this sense, SIRPα plays an important role in immune suppression.
In contrast, SIRPβ can potentially generate activation signaling
by associating with DAP12, but it cannot interact with CD47. In
addition, SIRPγ binds to CD47 with 10-fold lower affinity as com-
pared to SIRPα, but lacks a signaling motif (Barclay and Brown,
2006). An X-ray crystallographic analysis indicated that the dif-
ference in the binding affinities of the SIRPs with CD47 is due to
the subtle differences in the loops, with direct and indirect effects
(Hatherley et al., 2008).
The other function of the SIRPs is to bind with Surfactant
Protein D (Sp-D). Sp-D is an important component of the pul-
monary surfactant involved in host innate immunity, and is
capable of binding most Gram-negative bacteria as well as sev-
eral Gram-positive bacteria, leading to increased opsonization
of bacteria. On the other hand, the binding of Sp-D to SIRPα
transmits the immune suppression signals, resulting in decreased
cytokine production (Gardai et al., 2003). Interestingly, the SIRPα
binding to SP-D was competed with lipopolysaccharide (LPS;
Fournier et al., 2012). These observations indicated that the anti-
inflammation signals through SIRPα are present in the absence
of pathogens, and once pathogens are present, Sp-D binds prefer-
ably to LPS or other bacterial carbohydrates, and then induces
the host innate immunity. Under such conditions, the absence of
ligand binding to SIRPα also elicits an increase in inflammation
(Gardai et al., 2003). One recent report demonstrated that SIRPβ
also binds to Sp-D, but with slightly lower affinity as compared to
SIRPα (Fournier et al., 2012). These results suggested that SIRPs
exhibit self/non-self discrimination and cooperatively modulate
the immuneresponses.
C-TYPE LECTIN-LIKE RECEPTORS
C-type lectin-like receptors (CLRs) are expressed on the cell sur-
face of various immune cells, to regulate the innate immune
systems. The term “C-type lectin” means Ca2+ dependent
carbohydrate-binding lectin. The CLRs contain a conserved motif,
either EPN (Glu-Pro-Asn) or QPD (Gln-Pro-Asp). This motif
is located in a structurally conserved loop, which is stabilized
by a disulfide bond with another conserved loop. The EPN
motif confers specificity for mannose-based ligands, whereas
the QPD motif is typical of the galactose-specific Carbohy-
drate Recognition Domain (CRD; Zelensky and Gready, 2005).
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The carbonyl side chains of these amino acid residues coor-
dinate Ca2+, form hydrogen bonds with individual monosac-
charides, and determine binding specificity. Due to the versa-
tile recognition ability of the CLRs (described in below), they
are known as pathogen associated molecular patterns (PAMPs)
recognition receptors. The CLRs are primarily involved in detect-
ing pathogens and subsequently triggering signaling pathways
to evoke various immune reactions. Meanwhile, a few CLRs are
known to act as immuno-repressive receptors. Interestingly, it
was demonstrated that Macrophage inducible C-type lectin (Min-
cle, also called CLEC4E) recognized not only the sugar compo-
nents from pathogens through the CRD but also proteins from
pathogens or self, through sites other than the CRD (discussed
in detail below). Here, we describe the detailed functions and
structures of several CLRs, including orphan CLRs that have
yet to be characterized, to shed light on the molecular mech-
anisms of the ligand recognition by the paired-receptor-type
CLRs.
CD94/NKG2
The CD94/NKG2 receptors are expressed on the surfaces of a
greater part of NK cells and some subsets of CD8+ T cells, and
belong to the CLRs. While CD94 is encoded by a single gene
and has extremely low polymorphism, the NKG2 molecules have
five isotypes (NKG2A, C, D, E, and F) and two splice variants,
NKG2B and NKG2H, derived NKG2A and NKG2E, respectively.
Five NKG2 molecules (NKG2A, B, C, E, and H) have been shown
to form disulfide-linked heterodimers with CD94. CD94/NKG2A
and B mediate inhibitory signaling through the ITIM of the
cytosolic region in NKG2s. In contrast, CD94/NKG2C, E, and
H induce activation signaling through the interaction between
a Lys residue within their transmembrane region and a nega-
tively charged residue in the ITAM-containing adaptor molecule,
DAP12.
The ligand of most CD94/NKG2s is the non-classical MHCI,
HLA-E (Borrego et al., 1998; Braud et al., 1998; Lee et al.,
1998; Brooks et al., 1999; Table 1). HLA-E is expressed in all
nucleated cells and has few polymorphisms, as compared to the
classical MHCI. HLA-E mainly presents the peptides derived
from the leader sequences of other MHCIs. Therefore, NK cells
monitor the MHCI expression level through the interactions
between the inhibitory NKG2A/CD94s and HLA-E. Thus, NK
cells interact with healthy cells, which show normal expression
levels of HLA-E, resulting in the inhibition of NK cell killing
activity.
The structure of CD94/NKG2A in complex with HLA-E loaded
with an HLA-G derived peptide has been determined (Kaiser et al.,
2008; Petrie et al., 2008; Figure 5A). NKG2A and CD94 interact
with theα1 andα2 helices of the peptide-binding region of HLA-E,
respectively, with charge complementarity. The presented peptide
is also recognized by CD94/NKG2A, while CD94 is mainly recog-
nized HLA-E and the peptide, as compared to NKG2A. The Arg
(P5) and Phe (P8) residues of the peptides contribute to bind-
ing with CD94/NKG2A (Figure 5B). P5Arg is conserved in the
leader sequence of MHCI, and its replacement with a Lys abol-
ished the interaction with CD94/NKG2A. Hydrophobic amino
acid residues, such as Phe and Leu, are conserved in P8 of the
leader sequence, and their replacement with Lys led to a dramatic
reduction in the binding ability of HLA-E with CD94/NKG2.
These data indicated that the Arg in P5 and the hydrophobic amino
acid residue in P8 are both indispensable for the interaction with
CD94/NKG2A.
FIGURE 5 |The complex structure of NKG2A/CD94 and HLA-E. (A) The
overall structure of the NKG2A/CD94/HLA-E complex (PDB ID: 3CDG).
NKG2A/CD94 recognizes the α1–α2 domain of HLA-E containing a peptide.
(B) The interface of NKG2A/CD94 and HLA-E. The residues interacting with
P5Arg of the peptide are depicted by red stick models, and P8Phe is shown
by a blue stick model.
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The interaction between CD94/NKG2 and HLA-E is associ-
ated with a wide range of diseases, such as virus infection and
cancer. For instance, HCMV utilizes the host’s CD94/NKG2 sys-
tem to grow. The leader sequence of the HCMV protein, UL40, is
identical to that of HLA-Cw3. The CD94/NKG2A on NK cells rec-
ognizes the HLA-E associated peptide, which is derived from the
leader sequence of the HCMV protein, on the infected cells, and
therefore its interaction inhibits NK cells from attacking infected
cells (Tomasec et al., 2000; Ulbrecht et al., 2000). In addition, in
renal cell carcinoma-infiltrating NK cells, the expression level of
CD94/NKG2A is relatively high. This led to the proposal that
tumor cells control the expression level of CD94/NKG2A, and
consequently the function of NK cells (Schleypen et al., 2003). It
might be plausible that other intracellular pathogens can also uti-
lize the CD94/NKG2A systems to escape from the host’s immune
system.
DENDRITIC CELL IMMUNORECEPTOR/DENDRITIC CELL
IMMUNOACTIVATING RECEPTOR
Dendritic cell immunoreceptor (DCIR; CLEC4A) is one of the
repressive CLRs. DCIR is expressed on the surface of various
immune cells, such as dendritic cells, monocytes, macrophages, B
cells and neutrophils (Bates et al., 1999). Although DCIR report-
edly binds HIV-1, no physiological ligands for DCIR have been
identified (Lambert et al., 2008). The ITIMs in the cytoplasmic
tails of DCIR serve to recruit SHP1 or SHP2 after ligand binding
(Richard et al., 2006). The Syk and Src kinases (i.e., Src, Fyn, and
Hck), as well as the PKC-γ MAP kinases (i.e., Erk1/2 and p38),
are reportedly involved in the subsequent signaling pathway and
finally inhibit TLR8-mediated IL-12 and TNF-α production sig-
nificantly (Lambert et al., 2011). However, the precise mechanism
of this inhibition is still unknown.
DCIR expression on neutrophils was reportedly down-
regulated by TNF-α, IL-1α, and LPS stimulation, but was not
affected by anti-inflammatory stimuli, including IL-4, IL-10, and
IL-13 (Bates et al., 1999; Richard et al., 2002). These results
suggested that DCIR may be down-regulated during pathogen
exposure and inflammation.
A recent study showed that Dcir−/− mice developed joint
abnormalities, such as swelling and redness, at an early age,
and these abnormalities eventually progressed to joint defor-
mity and ankylosis (Fujikado et al., 2008). The Dcir−/− mice
developed sialadenitis, which is characterized by the accumu-
lation of lymphocytes in the interstitium and the destruc-
tion of the small duct associated with mononuclear cell
infiltration. The number of activated CD4+ T cells, the
expression of IL-4 and IL-10, and the production of IgG1
and IgG3 were increased in Dcir−/− mice. Furthermore, in
Dcir−/− mice, stimulation with granulocyte-macrophage colony–
stimulating factor (GM-CSF) activated the phosphorylation
of STAT5 and effectively differentiated bone marrow-derived
cells to dendritic cells, as compared to wild type mice. These
results suggested that DCIR regulates the proliferation of
dendritic cells and is involved in maintaining immune self-
tolerance.
On the other hand, mouse DCIR shares substantial sequence
homology (91% aminoacid identity) in the extracellular region
with its activating counter member, Dendritic cell immunoacti-
vating receptor (DCAR). DCAR is expressed similarly in tissues
to DCIR, but its short cytoplasmic portion lacks a signaling motif
such as an ITIM (Fujikado et al., 2008). Instead, an Arg residue
is present in the transmembrane region of DCAR, which partici-
pates in the association with the FcRγ chain and finally activates
immune cells. Neither the human ortholog nor the ligands for
DCAR have been identified yet.
NKR-P1 (CD161)
NKR-P1 (CD161) is expressed on the surfaces of NK cells and sub-
sets of T cells. Human NKR-P1 reportedly interacts with Lectin-
like transcript-1 (LLT1, also called CLEC2D), which is expressed
on many cell lines and on activated primary B cells (Aldemir et al.,
2005; Rosen et al., 2005). TheNKR-P1 and LLT1 genes are adjacent
on human chromosome 12, and coordinately regulate the immune
response. Rodents possess several Nkrp1 genes for the activating
(NKRP1-A, C, and F) and inhibitory (NKRP1B and G) receptors,
while in contrast, there is only a single inhibitory NKR-P1A gene
in human. LLT1 (also known as Clr-b in mouse) on target cells
can inhibit NK cytotoxicity, by interacting with NKR-P1 on NK
cells (Rosen et al., 2008). In rodents, NKR-P1C reportedly asso-
ciates with the FcRγ chain, inducing not only cytotoxicity but also
IFN-γ production. These data suggested that, although anon-self
ligand has not been identified, the components of pathogens or
dead cells may potentially stimulate NK cells through NKR-P1,
and are eliminated by NK cells themselves and by other immune
cells (Arase et al., 1997). The detailed molecular mechanisms of
both the activating and inhibitory signaling pathways via NKR-P1
have not been characterized, but interestingly, the acid sphin-
gomyelinase reportedly binds to the cytosolic region of NKR-P1
and participates in NK cell resistance to apoptosis (Pozo et al.,
2006). We recently analyzed the molecular basis of the inter-
action between NKR-P1A and LLT1 (Figure 6A; Kamishikiryo
et al., 2011), and proposed a model of the NKR-P1/LLT complex.
The constructed model suggested that the membrane-distal head
region of NKR-P1 is a new target to inhibit the NKR-P1-LLT1
interaction, potentially leading to the regulation of autoimmune
and chronic inflammatory disorders.
OTHER C-TYPE LECTIN-LIKE RECEPTORS
Other CLRs have been identified and functionally investigated.
Macrophage inducible C-type lectin (Mincle, also called CLEC4E)
is a type II transmembrane C-type lectin receptor expressed in
macrophages, dendritic cells and monocytes. Mincle was initially
identified as a gene up-regulated by LPS stimulation (Matsumoto
et al., 1999). The first identified ligand of Mincle was the spliceo-
some associated protein 130 (SAP130), the endogenous protein
released from necrotic cells (Yamasaki et al., 2008). Intriguingly,
Mincle also reportedly recognized malassezia species andMycobac-
terium tuberculosis (Ishikawa et al., 2009; Yamasaki et al., 2009).
While the ligand structures of the malassezia species are not
known, that of M. tuberculosis was identified as trehalose-1,1-
dimycolate (TDM). The malassezia species and M. tuberculosis
are both recognized through the CRD of Mincle. Following the
binding of either SAP130, malassezia species or TDM, Mincle asso-
ciates with the ITAM-bearing FcRγ chain. This association leads
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FIGURE 6 | Schematic model of LLT1 recognition by NKRP1 and
comparison of the structures of the Ly49-MHCI complex and m157. (A)
The model structures of LLT1 (cyan) and NKRP1 (blue) are shown by ribbon
models. Residues that may contribute to the interaction with LLT1 are shown
as spheres, with detrimental effects in red, and modest effects in orange.
Magenta spheres indicate the pair of residues that showed detrimental
effects when mutated independently, but restored the binding when mutated
simultaneously (Kamishikiryo et al., 2011). (B) The crystal structure of Ly49C
with H-2Kb (H-2Kb in green, β2m in cyan, Ly49C in blue; PDB ID: 1P4L). Ly49C
interacts with the β2m subunit and the α3 domain of H-2Kb, but not with the
peptide-binding region. The crystal structure of m157 (PDB ID; 2NYK). (C) The
mutation sites that identified the Ly49H binding residues are mapped and are
shown in stick style (red). The residues did not overlap with the interface of
the Ly49-MHCI complex structure.
to the phosphorylation of the ITAM of the FcRγ chain and the
subsequent recruitment of Syk, activating the caspase recruitment
domain family, member 9 (CARD9)-mediated NF-κB signaling
pathway to promote the expression of TNF and IL-6. A recent
report revealed that Mincle would likely playa non-redundant role
for T cell immune responses to infection by microbes (Schoenen
et al., 2010).
The Dendritic Cell-Specific Intercellular adhesion molecule-
3-Grabbing Non-integrin (DC-SIGN, also called CLEC4L and
CD209) proteins have been extensively studied, due to their broad
range recognition of pathogens and ligands from viruses to par-
asites, such as HIV-1, measles, dengue, SARS, Helicobacter pylori,
E. coli, Leishmania spp., and Schistosoma egg (Sancho and Reis
e Sousa, 2012). The binding of DC-SIGN with ligands from
pathogens activates human myeloid dendritic cells through var-
ious pathways. Mannose-expressing M. tuberculosis and HIV-1
promote the activation of LARG and RhoA, which function as
upstream activators of Raf-1 via DC-SIGN (Gringhuis et al., 2007,
2009; Hodges et al., 2007). This activation is mediated by the phos-
phorylation and acetylation of NF-κB subunit p65, which greatly
enhances the transcriptional activity of NF-κB and results in the
modulation of TLR4 signaling and the enhanced expression of
IL-10, IL-12, and IL-6 (Gringhuis et al., 2007). In contrast, fucose-
expressing pathogens, such as H. pylori, actively dissociated the
KSR1–CNK–Raf-1 complex and enhanced the expression of IL-10,
but down-regulated the expression of IL-12 and IL-6 in a Raf-
1-independent, but LSP1-dependent, manner (Gringhuis et al.,
2009). Notably, DC-SIGN cannot activate NF-κB by itself, and it
modulates the p65 activity only when p65 is induced by another
receptor upon the stimulation of mannose-expressing pathogens
(Gringhuis et al., 2007). In summary, the signaling via DC-SIGN
is tightly regulated by the characteristics of the ligands.
DC NK lectin group receptor-1 (DNGR, also called CLEC9A)
was previously shown to function as a Syk-coupled C-type lectin
receptor, to mediate the sensing of necrosis (Sancho et al., 2009).
A recent report demonstrated that DNGR recognized exposed
actin filaments from necrotic or damaged cells (Ahrens et al.,
2012; Zhang et al., 2012). Mutational and crystallographic studies
indicated that two exposed tryptophan residues in DNGR, which
are conserved between human and mouse, are involved in the
recognition of the actin filament. These residues are far from
the C-type lectin domains, which function in stabilizing the
structure of the protein, rather than being directly involved
in the receptor-ligand interaction. So far, most of the ligands
from pathogens are carbohydrate or carbohydrate-related prod-
ucts. However, several studies have clearly proved that CLR can
interact with ligands through other regions than the C-type
lectin domains. These results imply that non-carbohydrate lig-
ands of the CLRs from pathogens will be discovered in the
future.
DISCUSSION
Paired receptors are potentially dangerous, because activating
receptors can disrupt homeostasis, thus threatening life. In the
immune system, immune cells express such activating receptors
on their cell surfaces; however, the education or licensing of these
cells has been considered to require the expression of at least one
inhibitory receptor to suppress inappropriate activation, at least
in fully responsive mature cells. On the other hand, Arase et al.
(2002) clearly showed excellent evidence for one paired recep-
tor family, the Ly49 family. The susceptibility to mouse CMV
(MCMV) depends on the mouse strain, and the protection of this
virus is mediated by NK cells. Mice harboring only the inhibitory
Ly49 family members, which bind to MHCIs (Held et al., 1996;
Yu et al., 1996; Hanke et al., 1999) as well as the CMV MHCI
homolog, m157 (Arase et al., 2002; Smith et al., 2002), cannot
survive the CMV infection. However, other mice with the acti-
vating member, Ly49H, which binds to its m157 to activate the
immune response, can evade CMV infection. Thus, m157 is the
only known viral ligand binding to both inhibitory and activat-
ing receptors. Based on these observations, we have developed a
scenario in which the activation receptor evolved from the related
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inhibitory receptor in response to selective pressure imposed by
the pathogen, thus providing the presence of diversified, paired
receptors (Figure 1B). In accordance with this scenario, the acti-
vating receptor, KIR2DS2, has a relic of the ITIM sequence, which
is inactivated by the direct introduction of a stop codon (Arase
and Lanier, 2004). This hypothesis suggests that other activating
receptors will also recognize pathogen-derived ligands. Although
m157 forms a typical MHCI-fold, it neither presents a peptide
nor associates with β2m (Adams et al., 2007; Figures 6B,C).
A comparison of the crystal structures of the Ly49/H-2 com-
plexes and m157 revealed that a different interaction interface
from that of Ly49/H-2 would exist upon the binding of Ly49s
to m157.
Furthermore, Barclay and Hatherley (2008) proposed an ele-
gant counterbalance theory. Accumulating mutations on paired
receptors are often unrelated to the binding regions to physio-
logical ligands, which may support the idea that these mutations
are targeted to the non-self molecules of infectious microorgan-
isms. As described above, the ancestral paired receptors are likely
inhibitory to suppress undesired immune responses, but this is
essentially beneficial for microorganisms, if they can be used as
not only entry receptors but also inhibitory ones to facilitate
immune evasion. The KIRs are considered to have co-evolved
with their ligands, the MHCIs. For example, different human
populations have a reciprocal relationship between the KIR and
HLA-C frequencies (Hiby et al., 2004), and the frequency of the
KIR2DL3-HLA-C1 combination could be reduced in populations
highly exposed to malaria, by natural selection (Hirayasu et al.,
2012). These observations suggested that the paired receptors and
their ligands co-evolved. Therefore, the precise understanding of
the on-going activating and inhibiting balance of paired recep-
tors can provide insight into the extent of the importance of
each set of paired receptors for immune defense. In this sense,
the development of small molecular-weight compounds or bio-
pharmaceuticals targeting paired receptors can more easily and
finely regulate the immune responses, as advanced therapy for
either infectious diseases or tumorigenesis. Especially, we believe
that future accumulating information relating the genetic, mole-
cular, and structural bases for paired receptors will greatly con-
tribute to the development of novel therapies with fewer side
effects.
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